Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Mesenchymal Stem Cells in Veterinary Medicine-Still Untapped Potential

Morawska-Kozłowska M., Pitas M., Zhalniarovich Y.

Narrative Review on Osteoarthritis, Chronic Kidney Disease, Immune Modulation, published in Animals (Basel) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Animals (Basel) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40282009
PMCID
PMC12024326
DOI
10.3390/ani15081175
Citations
4

Abstract (original English)

Mesenchymal stem cells (MSCs) hold significant therapeutic potential in veterinary medicine due to their regenerative and immunomodulatory properties. This review examines the clinical applications of MSCs across multiple animal species, including equine, canine, feline, and bovine medicine. MSC therapies have demonstrated promising outcomes in treating musculoskeletal disorders, osteoarthritis, inflammatory diseases, and tissue injuries, particularly in horses and dogs. In cats, MSCs show potential for managing chronic kidney disease, inflammatory bowel disease, and asthma, while in bovine medicine, they offer alternative treatment approaches for mastitis and orthopedic injuries. Despite these advancements, challenges such as treatment standardization, cell sourcing, and potential adverse effects, including tumorigenicity, remain under investigation. The emerging field of MSC-based veterinary medicine highlights its capacity to enhance healing, reduce inflammation, and improve clinical outcomes. However, further research is necessary to optimize treatment protocols and address safety concerns, ensuring the widespread adoption of MSC therapies in veterinary practice.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research